Kyverna's One-Year Data Clears a Key Hurdle, but Can a $500 Million Biotech Win the Race to Make CAR-T Work for Autoimmune Disease?

Shares of Kyverna Therapeutics surged 13.1% to $8.00 Wednesday morning after the company reported that its lead cell therapy produced durable responses with a clean safety profile through one full year in two autoimmune diseases — a milestone that inches the firm closer to a historic first-of-its-kind FDA approval.

• One Dose, One Year, No Major Side Effects — That's the Headline That Matters. Kyverna announced positive one-year data from its registrational trial in stiff person syndrome (SPS) and longer-term follow-up from its Phase 2 trial in generalized myasthenia gravis (gMG).

The therapy showed durable clinical responses in both diseases with no high-grade adverse effects.

In the SPS trial of 26 patients, the median improvement in a timed walking test was 49% at month 12. For autoimmune patients who often endure lifelong immunosuppressive drugs, a single infusion that holds up at one year is a radical shift — and exactly the durability story the FDA needs to see.

• The FDA Filing Is on Schedule, With a Potential 2027 Launch. Kyverna intends to include the one-year data in its rolling Biologics License Application (BLA), on track for completion in Q4 2026.

The company has already submitted the manufacturing module and plans to seek priority review, targeting a potential 2027 launch.

If approved, this would be the first FDA-approved CAR-T cell therapy for autoimmune disease — a distinction that could define the company's commercial value.

• The Cash Runway Supports the Plan — Barely. Kyverna held $199.4 million in cash and securities as of June 30, 2026, which, with its Oxford Finance loan facility, is expected to fund operations into 2028.

The company burned $38.3 million in Q2 alone. With no revenue, a pre-commercial launch buildout ahead, and an accumulated deficit of $502.9 million , additional fundraising before any product sales remains virtually certain.

• Wall Street Is Bullish, but Shorts Are Betting Against It. Six analysts rate the stock a "Strong Buy" with an average 12-month price target of $30.40 — more than triple the current price. Yet short interest stands at 7.8 million shares, or 14.1% of the float, up 481.9% since August 2025, reflecting notable bearish positioning. Today's data may force some of that short trade to unwind, but the market is clearly split on whether Kyverna can convert trial success into commercial reality.